Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in Treatment Refractory Psychotic Illness
NCT02808533Active, not recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- May 2016
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in schizophrenia, schizoaffective disorder and obesity comparing Topiramate with Placebo (2 arms). Primary endpoint: Weight loss at 16 weeks. Started May 2016; status: active, not recruiting.
02
Drugs
topiramate
03
Conditions
schizophreniaschizoaffective disorderobesity
Beyond the preview
Go deeper on NCT02808533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808533.